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Abstract
Cholera toxin (CT) is a mucosal adjuvant capable of inducing strong immune responses to co-administered antigens
following oral or intranasal immunization of mice. To date, the direct effect of CT on antigen-specific CD4+ T cell migration
and proliferation profiles in vivo is not well characterized. In this study, the effect of CT on the migration pattern and
proliferative responses of adoptively transferred, CD4+ TCR transgenic T cells in orally or intranasally vaccinated mice, was
analyzed by flow cytometry. GFP-expressing or CFSE-labeled OT-II lymphocytes were adoptively transferred to naı¨ve C57BL/
6 mice, and mice were subsequently vaccinated with OVA with or without CT via the oral or intranasal route. CT did not alter
the migration pattern of antigen-specific T cells, regardless of the route of immunization, but increased the number of
transgenic CD4+ T cells in draining lymphoid tissue. This increase in the number of transgenic CD4+ T cells was not due to
cells undergoing more rounds of cellular division in vivo, suggesting that CT may exert an indirect adjuvant effect on CD4+ T
cells. The findings reported here suggest that CT functions as a mucosal adjuvant by increasing the number of antigen
specific CD4+ T cells independent of their migration pattern or kinetics of cellular division.
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Introduction
Cholera toxin (CT) is a well characterized mucosal adjuvant
capable of inducing strong immune responses to co-administered
antigens [1] following intravenous, oral, intranasal or sublingual
immunization [2–4]. CT is a multimeric protein produced by
Vibrio cholerae, consisting of a pentameric ring of B subunits
associated with a single A subunit. The CT-B subunit binds the
GM1 mono-sialo ganglioside, which is found in high abundance
on the luminal surface of intestinal epithelial cells [5,6]. The
binding of CT to the cell membrane mediates ADP-ribosylation of
an adenylate cyclase regulatory protein [7], resulting in increased
intracellular cAMP concentrations. The increase in cAMP levels
leads to changes in ion channels, the accumulation of Na+ and Cl2
ions in the gastrointestinal lumen, and a massive flow of water and
electrolytes from epithelial cells [8]. The toxicity of CT for humans
is extreme, as 5 mg of orally ingested CT leads to the production of
more than 1 liter of diarrhea [9].
CT is a strong mucosal adjuvant and is thought to facilitate
luminal antigen transport across the epithelium by increasing gut
permeability, allowing antigens to access the gut mucosal immune
system and induce an immune response [10]. In this way, CT
mediates increased antibody production [11] and induces cyto-
toxic T lymphocyte activity when co-administered with antigen via
the oral [12], intranasal, and subcutaneous routes [13]. The oral
co-administration of soluble antigen with CT promotes priming of
CD4+ T cells [14], elicits systemic Th2 activity [15,16] and
enhances the proliferation of lymphocytes to antigen [14]. This
results primarily in the development of a Th2-like immune
response to co-administered antigens, with increased production of
IL-4, IL-5 and IL-10, and provides help for B cells to produce
IgG1, IgA and IgE antibodies [11,17,18]. Indeed, CD4+ T cells
are essential for the development of antigen-specific antibody
responses following mucosal administration of both antigen and
CT [19].
More recently, the effect of CT on antigen presenting cells has
been elucidated. Conventional DCs (cDCs) are essential for the
development of antigen-specific antibody responses following oral
vaccination with CT and antigen [20]. This is due to the direct
effect of CT on cDCs, inducing their migration into the follicle-
associated epithelium as early as one hour after encountering CT
[20]. Furthermore, cDCs are required for priming of CD4+ T cells
following nasal or oral administration of protein with CT [20].
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This may be due to the ability of CT to induce the upregulation of
costimulatory molecules such as B7.2 on B cells, macrophages and
dendritic cells (DCs) [17,21,22] and B7.1, B7.2, OX-40 and HLA-
DR molecules on human DCs that can prime naı¨ve CD4+ T cells
in vitro, driving their polarization towards a Th2 response [23–25].
The ability of CT to upregulate costimulatory molecules on DCs
may function in unison with its ability to induce the expression of
functional CCR7 and CXCR4 chemokine receptors on DCs,
enabling them to migrate towards secondary lymphoid organs and
present antigen to T cells [23].
Despite the plethora of studies describing the adjuvant effect of
CT and its effect on DC migration, its effect on antigen-specific
CD4+ T cell migration into non-lymphoid and secondary
lymphoid tissue, and the kinetics of in vivo proliferation, have not
been defined to date. In addition, the effect of CT administration
via various mucosal routes on T cell migration and proliferation
has not been examined. Studies examining the direct effect of CT
on T cells may further explain its adjuvanticity and aid the
development of an alterative CT-based adjuvant suitable for
human use. This study utilized the adoptive transfer of transgenic
T cells to study in vivo antigen-specific, CD4+ T cell responses in
the presence of the mucosal adjuvant CT. The migration pattern,
number of antigen-specific T cells and the kinetics of antigen-
specific CD4+ T cell division in response to oral or intranasal
administration of antigen and CT were examined. This study
established that CT acts by increasing the number of antigen-
specific T cells regardless of the route of vaccination. This antigen
specific CD4+ T cell increase did not appear to be due to an
alteration in the migration profile of antigen-specific T cells in vivo,
nor to an alteration in the kinetics of cellular division. However,
the overall increase in antigen-specific cell number may be the
result of more efficient activation of DCs, leading to cell division
by an increased number of the fixed pool of antigen-specific cells.
Materials and Methods
Ethics Statement
All animal experiments were approved by The University of
Melbourne Animal Ethics committee and performed in accor-
dance with the Prevention of Cruelty to Animals Act (1986) and
the NHMRC Code of Practice for the Care and Use of Animals
for Scientific Purposes.
Mice
Six to nine week old C57BL/6, C57BL/6gfp+/2 (referred to as
B6.GFP mice) [26], B6.OT-II (OVA-specific, MHC class II
restricted TCR transgenic mice) [27] and B6.OTIIgfp+/2 mice
(this study) were bred and housed at the animal facility of the
Department of Microbiology and Immunology, The University of
Melbourne. B6.OTIIgfp+/2 mice used in this study were generated
by crossing transgenic homozygous B6.OT-II with C57BL/6gfp+/
2. These mice were mated to obtain heterozygous F1 offspring
with the genotype C57BL/6gfp+/2 OT-II+/+. All mice were
housed under specific pathogen free conditions and fed sterile
food and H2O ad libitum. Mice were euthanized by carbon dioxide
asphyxiation. All mice were age and sex matched for each
experiment.
Preparation of Lymphocyte Suspensions from Spleen and
Lymph Nodes
Spleens were gently passed through a 40 mm-gauge wire mesh,
and erythrocytes were lysed by incubation in NH4Cl-Tris solution
(pH 7.2) at 37uC for 5 minutes. The cells were collected by
centrifugation and resuspended in Hanks Balanced Salt Solution
(HBSS) supplemented with 2.5% (v/v) fetal calf serum (HBSS/
2.5% FCS). Lymph node (e.g. brachial, mesenteric, cervical and
paragastric lymph node) cell suspensions were prepared in HBSS/
2.5% FCS by gently teasing whole tissues through a 40 mm-gauge
wire mesh. Cells were collected by centrifugation and resuspended
in HBSS/2.5% FCS.
Peyer’s Patch (PP) Lymphocyte Preparations
PP lymphocytes were prepared as previously described [28]. In
brief, PP were removed from the intestine and incubated with
HBSS/0.25 M EDTA to remove epithelial cells. Treated PP were
then minced with a scalpel blade and further incubated with
200 mg/ml collagenase D (Boehringer Mannheim, Mannheim,
Germany) and 40 mg/ml DNase I (Boehringer Mannheim,
Mannheim, Germany) for 45 minutes at 37uC with gentle
agitation. Single cell suspensions of the digested PP were prepared
by passing the tissues through a 40 mm-gauge wire mesh.
Preparation of Intraepithelial (IEL) and Gut Lymphocytes
IELs were prepared using a modification of a method described
previously [29]. In brief, the small intestine was dissected, the
intestinal contents were flushed out, and PP and mesentery were
removed. The intestine was cut longitudinally, then into 2 cm to
3 cm lengths and incubated with 5 mM EDTA (pH 7.2). After
washing, remaining mesentery was removed with the aid of
a dissecting microscope. The segments were incubated with
100 U/ml collagenase D, 1.5 mg/ml DNase-I, and 1.5 mg/ml
soybean trypsin inhibitor (Worthington, NJ, USA) for 15 minutes
at 37uC. This digested fraction contained the IEL. Undigested
tissue was sedimented by centrifugation at low speed, and the IELs
were recovered from the supernatant. The remaining intestinal
segments were incubated for 1 to 2 hours with the collagenase mix
until completely digested. Cells recovered from this fraction were
termed the gut cellular preparation.
Isolation of Gastric Mucosal Lymphocytes
Lymphocytes were isolated from the gastric mucosa of mice
using the ‘‘ballooning’’ method as previously described [30]. PBS/
5% (v/v) FCS (10 ml) was injected into the mucosa of the stomach,
forcing the tissue to swell and rupture, consequently releasing
lymphocytes. This ‘‘ballooning’’ was performed along the whole
surface of the stomach. Lymphocyte suspensions obtained were
passed through nylon mesh to remove tissue debris.
Isolation of Nasal Associated Lymphoid Tissue (NALT)
Lymphocytes were isolated from the NALT of mice as
previously described [31].
Adoptive Transfer of CFSE-labeled Lymphocytes
Lymphocytes from donor B6.OTIIgfp+/2 or B6.OT-II mice
were prepared from renal, mesenteric, cervical, brachial, auxiliary
and lumbar lymph nodes. Single cell suspensions of lymphocytes
were prepared and OT-II lymphocytes were labeled with the
fluorescent dye CFSE (Molecular probes, OR, USA) [32]. In brief,
107 lymphocytes were resuspended in 1 ml of HBSS/0.1% (w/v)
BSA with 1 mM/ml of CFSE. Cells were labeled at 37uC for 10
minutes, washed twice with HBSS/2.5% (v/v) FCS, and finally
resuspended in HBSS. Mice were injected intravenously (i.v.) with
56106 B6.OTIIgfp+/2 (referred to as GFP+/2 OT-II cells) or
CFSE-labeled B6.OT-II cells (referred to as CFSE-labeled OT-II
cells) in 200 ml PBS, unless otherwise stated.
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Intranasal Administration of Evans Blue
Evans blue dye (BDH, England) (0.3% w/v in PBS) was
administered to Penthrane anaesthetised mice (Medical Develop-
ments Australia Pty Ltd, Australia) via a micropipettor fitted with
a 200 ml pipette tip. Mice were held in an upright position, and
either 12 ml or 20 ml of Evans blue dye was gradually applied to
the nares, allowing mice to inhale the dye. Mice were euthanized
either immediately, 1 hour, 4 hours or 24 hours after Evans Blue
administration and the location of the dye was determined by
examining the organs (oesophagus, trachea, lungs, stomach and
intestine) in situ.
Immunization of Mice
One day after intravenous (i.v.) adoptive transfer of CFSE-
labeled OT-II cells or GFP+/2 OT-II cells into recipient C57BL/6
mice were anaesthetized by Penthrane inhalation (Medical
Developments Australia Pty Ltd, Australia) and OVA and/or
CT were administered orally by gavage. Mice were orally
immunized with 10 mg of CT (Sigma, St Louis, MO, USA),
15 mg of OVA (Sigma, St Louis, MO, USA), or a mixture of both,
made to 200 ml with PBS. For intranasal (i.n.) immunization,
anaesthetized mice were immunized with a 12 ml volume of either
PBS, 25 mg OVA, 5 mg CT or a mixture of 25 mg OVA and 5 mg
CT, gradually placed onto their nares.
Bone Marrow Derived Dendritic Cell (BMDC) Cultures
Bone marrow derived DC cultures were generated according to
Lutz et al. [33]. In brief, single cell suspension of bone marrow
obtained from the femurs of C57BL/6 mice were cultured in
RPMI 1640 supplemented with 10% (v/v) FCS and 10% (v/v)
GM-CSF supernatant (X63-GM-CSF, kindly provided by Pro-
fessor F. Carbone, The University of Melbourne). After 7 days of
culture, semi and non-adherent cells were collected and used for
all DC experiments. Cells were labeled with anti-CD11c and anti-
MHC II antibodies and analyzed using flow cytometry prior to
use.
In vitro Stimulation with Peptide Pulsed DCs
Antigen-loaded BMDCs were co-cultured with CFSE-labeled
OT-II cells as previously described [34]. BDMCs (46106/ml) were
incubated with CT (4.4 mg/ml), synthetic OVA323–339 peptide
(1 mg/ml) or CT with OVA peptide (Chiron technologies, Clayton
Vic, Australia) for 45 minutes at 37uC in RPMI (Gibco, USA)
[35]. BMDC were washed three times and added to 96 well
round-bottom plates at 56103 per well. Naı¨ve, CFSE-labeled OT-
II cells were cultured with BMDC at 56104 per well (NUNC,
Denmark). At various time points, dilution of CFSE dye was
analyzed using flow cytometry.
Flow Cytometry
Cells were labeled with fluorescently conjugated antibodies (BD
Biosciences, USA) to CD4 (Clone H129.19) and Va2 (Clone
B20.1) to enable identification of OT-II cells or to CD11c (Clone
HL3) and MHC II (I-Ab Clone 25-9-17) to label DC. When
indication, cells were labeled with antibody specific for the
adhesion molecule a4b7 (Clone DATK32). All samples were
acquired using a FACS Calibur (BD Biosciences, USA). Non-
viable cells were excluded from data acquisition on the basis of 0u
and 90u scatter profiles, and by their ability to exclude propidium
iodide. Data was analyzed using CellQuestTM software (BD
Biosciences).
Statistics
Data was analyzed using a two-tailed Student’s t-test or one-way
ANOVA as indicated. Differences were considered significant
when P,0.05, whereas P,0.01 represents greater statistical
difference.
Results
CT does not Affect the in vivo Migration Pattern of CD4+
T Cells in the Absence of Antigen
To determine the effect of CT on the migration of antigen-
specific T cells in vivo, GFP OT-II cells were adoptively transferred
into recipient C57BL/6 mice which were orally immunized with
either PBS (Figure 1A and C) or 10 mg CT (Figure 1B and D) the
following day. At 1 and 5 days after oral immunization, the
location of GFP+/2 OT-II cells in various organs was determined
using flow cytometry (Figure 1). At both time points, GFP+/2 OT-
II lymphocytes were detectable in all secondary lymphoid organs
analyzed, and as expected, negligible numbers of GFP+/2 OT-II
cells were detected in the (non-lymphoid) gut, stomach and in the
lamina propria among intraepithelial lymphocytes (IEL) of PBS-
control recipient mice. In comparison with PBS-fed mice, CT-
immunized mice had similar numbers of GFP+/2 OT-II cells in
lymphoid tissues and in non-lymphoid gastric tissue, suggesting
that administration of CT did not alter the migration of antigen-
specific T cells in vivo over time (Figure 1A–D).
Oral Administration of CT with Antigen Increases the
Total Number of Antigen Specific T Cells in vivo
We next examined if co-administration of CT with antigen
affects the migration pattern or the number of antigen-specific T
cells in the lymphoid tissues of mice. One day after adoptive
transfer of GFP+/2 OT-II lymphocytes, recipient C57BL/6 mice
were immunized orally with either 10 mg CT, 15 mg OVA, or
10 mg CT and 15 mg of OVA, or received PBS as a control. Mice
were euthanized either on day 1, when no OT-II cell proliferation
is evident, or day 5 after oral immunization, and the number of
GFP+/2 OT-II T cells in secondary lymphoid organs was
examined using flow cytometry (Figure 1E–G).
One day after feeding, there was no difference in the
distribution or the number of transgenic GFP+/2 OT-II (Va2
CD4+) T cells detected in any of the tissues of different groups of
immunized mice (data not shown). However, 5 days after oral
immunization, there was a significant increase in the number of
GFP+/2 OT-II cells in the MLN of OVA immunized mice
compared with PBS controls (P,0.05) (Figure 1E). Co-adminis-
tration of CT with OVA further increased the numbers of GFP+/2
OT-II cells in the MLN compared with immunization with OVA
alone (P,0.05). In the PP, the number of GFP+/2 OT-II cells
significantly increased in the CT and OVA immunized mice
compared with OVA alone (Figure 1G) (P,0.05, one way
ANOVA), while no effect on GFP+/2 OT-II cell number was
observed in the spleen of mice immunized with CT and OVA
compared with OVA alone (Figure 1F). No GFP+/2 OT-II cells
were detected in any non-lymphoid organs (stomach, IEL and gut)
analyzed (data not shown). Therefore, these data suggest that CT
functions to increase the number of OT-II specific T cells when
co-administered with OVA, without altering the migration pattern
of OVA-specific T cells in vivo.
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CT does not Alter the Rate of Antigen-specific Cells
Dividing in Response to Orally Administered Antigen
Stimulation in vivo
The increase in GFP+/2 OT-II T cell number observed in the
PP and the MLN after co-administration of OVA with CT
compared with OVA alone, could be due to either increased
number of T cells undergoing cellular division, an equivalent
number of cells undergoing more rounds of cellular divisions in
response to the antigen or be a consequence of enhanced
migration of GFP+/2 OT-II T cells into the MLN. Since CT
did not alter cellular migration patterns in vivo (Figure 1), the effect
of orally administered CT on the in vivo kinetics of antigen-specific
T cell division was determined.
CFSE-labeled OT-II cells were adoptively transferred to
recipient C57BL/6 mice and one day later mice were orally
immunized with either PBS, 10 mg CT, 15 mg OVA or 10 mg CT
and 15 mg OVA. The location of OT-II cells and dilution of
CFSE dye as a marker of the number of cellular divisions was
analyzed by flow cytometry five days after immunization (Figure 2).
A representative histogram of CFSE-labeled OT-II cells cells in
the MLN of immunized mice from each group is depicted in
Figure 2A. A single peak of undivided CFSE-labeled OT-II cells
was observed in MLN (Figure 2A) and PP (data not shown) after
immunization of mice with CT or PBS. No additive effect of co-
administration of CT to OVA antigen was noted in the MLN,
compared to OVA alone, as CFSE-labeled OT-II cells had
undergone 6 rounds of cellular division in each treatment group
Figure 1. Oral administration of CT increases the number of antigen-specific CD4+ T cells without altering their migration pattern
in vivo. GFP+/2 OT-II lymphocytes (56106) were adoptively transferred to C57BL/6 recipient mice and one day later the mice were orally immunized
with PBS (A, C) or 10 mg CT (B, D). One (A–B) and five days (C–D) after oral immunization, the number of GFP+/2 OT-II cells (identified as GFP+CD4+)
present in the spleen (SPL), mesenteric lymph nodes (MLN), peripheral lymph nodes (PLN), Peyers patches (PP), gut, intraepithelial lymphocyte
compartment (IEL) and stomach (STO) was determined by flow cytometry. The lymphocyte preparations from the IEL, STO and PP of mice were
pooled to obtain sufficient numbers of cells. Represented are the results from individual mice, as well as the average number of lymphocytes per
group (dash, n = 3). Lymphocytes from the PP of mice were pooled (n = 3 each). Results are representative of one out of three independently
performed experiments. E–G: GFP+/2 OT-II lymphocytes (56106) were adoptively transferred to C57BL/6 recipient mice. One day later, recipient mice
were orally immunized with either PBS, 10 mg CT, 15 mg OVA or 15 mg OVA with 10 mg CT. Five days after oral immunization, the number of
transgenic GFP+/2 OT-II (GFP, Va2, CD4+) cells present in MLN (E), spleen (F) and PP (G) was determined by flow cytometry. E–F: Symbols represent
results from individual mice obtained in 2 independently performed experiments, the columns represent the mean of each treatment group. G:
symbols represent the results from three independent experiments each performed with PP cells pooled from 3 mice, the column represents the
mean of the 3 experiments. *denotes P,0.05 (one way ANOVA).
doi:10.1371/journal.pone.0059934.g001
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Figure 2. CT induces an increase in the number of dividing OT-II cells without altering the number of cellular divisions in the
draining MLN. CFSE-labeled OT-II cells (56106) were i.v. injected into recipient C57BL/6 mice. One day later, mice were orally immunized with either
PBS (n = 3), 10 mg CT (n = 3), 15 mg OVA (n= 10) or 10 mg CT with 15 mg OVA (n= 10). Five days after immunization, MLN were removed and dilution
of CFSE from OT-II cells as a measurement of cellular division was analyzed using flow cytometry. Propidium iodide was used to exclude dead cells
from the analysis. A: Shown is a representative histogram from one individual animal of each group. B: Mice were analyzed for the total number of
CFSE-labeled CD4+ T cells within each cellular division. Shown are OVA fed (filled squares) and CT with OVA fed (filled circle) mice. Data is represented
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(Figure 2A). This data suggested that CT did not alter the rate of
cellular division of antigen-specific T cells.
To further analyze the effect of CT on antigen-induced
proliferation of T cells, the number of CFSE-labeled cells per
dividing peak located within the MLN was quantified (Figure 2B).
A greater number of CFSE-labeled OT-II cells were contained
within the first and second peak of division of mice fed CT with
OVA compared to mice that were fed OVA alone (P,0.05)
(Figure 2B), suggesting that CT administered with antigen
increased the number of dividing antigen-specific T cells.
Furthermore, when analyzing the total number of dividing (CFSE
low) OT-II cells present in the MLN of OVA and CT with OVA-
immunized mice, we noticed an increase in the number of dividing
CFSE-labeled OT-II cells in the latter group (Figure 2C),
suggesting that CT co-administered with OVA increased the
number of dividing antigen-specific T cells in vivo. Indeed, these
findings further support the data shown in figure 1, and suggest
that CT increased the number of antigen-specific T cells without
altering the kinetics of OT-II cell division.
Moreover, it has been reported that oral immunization with
CT+OVA induces the expression of a4b7 integrin on OT-I CD8+
T cells [36]. Therefore, we wished to examine the expression of
a4b7 integrin on CFSE-labelled CD4+ OT-II cells in the MLN,
PP and spleen 5 days post immunization. We identified that
CFSE-labelled CD4+ OT-II from PBS, CT, OVA and CT+OVA
immunized animals were negative in all organs for the expression
of a4b7 at 5 days post immunization. Hence, we concluded that
administration of CT with OVA does not alter the migration
pattern of CD4+ T cells, and does not induce the expression of
a4b7 at 5 days after immunization.
Intranasal Administration of CT and OVA Increased the
Total Number of Antigen-specific T Cells in vivo
Since CT is also used as an adjuvant administered via the i.n.
route [37,38], this study continued to examine the adjuvant effect
of i.n. administered CT on antigen-specific T cells. First, the
optimal volume that can be administered i.n. with minimal
amount of fluid entering the gastrointestinal and/or lower
respiratory tract was determined, using Evans Blue dye in
increasing volumes. Careful monitoring of the location of dye in
situ revealed that a 12 ml volume dose remained in the upper
respiratory tract and was absent from the gastric tissue, and this
volume was used for all subsequent i.n immunization studies
(Table 1). Subsequently, the minimum amount of OVA admin-
istered i.n. to B6.OT-II-recipient mice was titrated and 25 mg was
selected as the optimal dose, based on the observation that
proliferation of CFSE-labeled OT-II cells was detected in all
animals immunized with this dose of OVA (data not shown).
To examine the effect of i.n. administered CT on antigen-
specific T cells numbers in vivo, GFP+/2 OT-II lymphocytes were
adoptively transferred to recipient C57BL/6 mice. One day later,
mice were i.n. immunized with either PBS, 5 mg CT, 5 mg CT
with 25 mg OVA or 25 mg OVA in a 12 ml volume. Mice were
euthanized 1 and 5 days after i.n. immunization and the number
of GFP+/2 OT-II T cells within each organ was enumerated by
flow cytometry (Figure 3). One day following immunization, an
equivalent number of GFP+/2 OT-II cells were located within the
peripheral lymph node (PLN, i.e. brachial), cervical lymph node
(CLN), MLN and mediastinal lymph nodes (MeLN, pooled groups
of 3 mice) of all mice (data not shown).
At five days after i.n. immunization, no differences were
observed in the number of GFP+/2 OT-II cells in the PLN and
MLN between various treatment groups (Figure 3). In the CLN,
significantly more (P,0.05, one way ANOVA) GFP+/2 OT-II
cells were detected in mice treated with CT and OVA compared
with the other treatment groups (Figure 3). A similar trend was
observed in the MeLN, where increased numbers of GFP+/2 OT-
II were detected following treatment with CT and OVA or OVA
alone compared with PBS or CT treated mice (Figure 3). The
analysis of nasal associated lymphoid tissue (NALT) from all
groups of animals revealed negligible numbers (,100) of OT-II T
cells present within this compartment, therefore no further analysis
of OT-II cells in the NALT was performed in this study. Thus, the
findings of this experiment suggested that similar to oral
administration, CT administered via the i.n. route increased the
total number of antigen-specific T cells in the draining MeLN and
the CLN but not at other sites.
The Number of CFSE-labeled OT-II Cells Increased
Following i.n. Administration of CT and OVA without
Altering the Kinetics of Cellular Divisions
To determine whether the increased number of OT-II cells
present in the draining MeLN of CT and OVA i.n immunized
mice was due to enhanced local proliferation, or an alteration of
the kinetics of division, we analyzed the migration and pro-
liferation pattern of CFSE-labeled OT-II cells using flow
cytometry five days following i.n. immunization (Figure 4).
Transgenic OT-II cells were labeled with the fluorescent dye
CFSE and adoptively transferred into C57BL/6 mice. The
following day, mice were i.n. immunized with PBS, 5 mg CT,
5 mg CT with 25 mg OVA or 25 mg OVA alone. One and five
days after immunization, cellular suspensions of secondary
lymphoid organs were analyzed by flow cytometry to determine
the location and the level of proliferation of antigen specific T
cells. One day after i.n. immunization, no proliferation of OT-II
lymphocytes was observed in any of the tissue analyzed (data not
shown). Five days after immunization, dividing CFSE-labeled cells
were detected in the CLN and MeLN of the OVA and CT with
OVA immunized mice, and at both sites the OT-II cells had
undergone 4 detectable rounds of cellular division (Figure 4A). No
proliferation was detected in the CLN and MeLN of CT and PBS
immunized mice. In addition, no dividing CFSE-labeled cells were
detectable in the MLN and PLN (data not shown) of any mice,
irrespective of the vaccination, suggesting that little or no antigen
had entered the gastrointestinal tract and dividing cells had not re-
circulated.
We next performed further analysis of the total number of
CFSE-labeled OT-II cells that had divided in the MeLN and CLN
of mice i.n immunized with OVA or CT with OVA 5 days post
vaccination (Figure 4B, 4C). In comparison to OVA-immunized
mice, there was a greater than 2 fold increase in the number of
proliferating OT-II cells in the MeLN and CLN (P,0.05) of CT
with OVA immunized mice, suggesting that i.n administered CT
increased the number of antigen-specific T cells in draining LN
through increased number of proliferating cells.
as the mean 6 SEM of each group of mice (n = 10). *denotes P,0.05, Students’ t-test. C) The total number of CFSE-labeled, viable CD4+ T cells per
56105 lymphocytes is shown. All data are representative of 2 independent experiments and represented as the mean 6 SEM of each group of mice.
doi:10.1371/journal.pone.0059934.g002
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CT does not Alter the Kinetics of Cellular Division of
CFSE-labeled OT-II Cells Stimulated with Peptide Pulsed
DCs in vitro
The results from this study suggested that orally or i.n.
administered CT increased the number of antigen-specific T cells
and did not alter the number of cellular divisions of antigen-
specific T cells detected at a particular timepoint in vivo. There are
several parameters that cannot be controlled when performing in
vivo studies, the key one being migration of stimulated antigen-
specific T cells from one site to another. To eliminate the
possibility that activated, CFSE-labeled cell migration out of the
MLN or MeLN in immunized mice affected the findings of the
experiment, an in vitro experiment was performed to determine if
CT alters the kinetics of cellular division.
Bone marrow derived dendritic cells (BMDCs) were pulsed with
either 1 mg OVA323–339 peptide or with the same amount of
OVA323–339 peptide mixed with CT, and were cultured for 4 days
with CFSE-labeled OT-II cells. Flow cytometry was used to
analyze BMDC-induced cellular division of the CFSE-labeled
OT-II (Figure 5). BMDC pulsed with CT alone or media did not
induce proliferation of CFSE-labeled OT-II cells, indicating any
detected cellular division was antigen driven. Stimulation with
OVA323–339 peptide induced 5 rounds of division (Figure 5).
Incubation of BMDC with CT and OVA323–339 increased the total
number of dividing CFSE-labeled OT-II cells, indicated by the
larger peaks at each stage of cellular division (Figure 5).
Comparable results were obtained at days 2 and 3 post
stimulation, indicating that cells were not dividing faster at any
timepoint analyzed (data not shown). Similarly, an increased
number of proliferating OT-II cells but no difference in number of
cellular divisions was observed in cultures in which BMDC were
pulsed with OVA or with CT and OVA (data not shown).
Discussion
In this study, adoptive transfer of naı¨ve, fluorescently-labeled
transgenic lymphocytes was used to model the behavior of antigen-
specific T cells in vivo following immunization with CT and
antigen. To trace the adoptively transferred lymphocytes, cells
were either labeled with the intracellular fluorescent dye CFSE, or
were obtained from GFP transgenic animals. The fluorescent dye
CFSE is a widely used immunological tool enabling the
monitoring of cellular division and migration pattern of lympho-
cytes in vivo [39,40]. However, during periods of extensive
stimulation and cellular division of CFSE-labeled lymphocytes,
fluorescence may be lost due to exhaustion of the fluorochrome.
Unlike CFSE-based fluorescence, GFP-based fluorescence is not
lost following division of cells. In this study, we used heterozygous
B6.GFP+/2 mice [26], as homozygous GFP mice exhibit growth
retardation and die at 4 to 6 weeks of age due to unknown causes
[41] were mated to homozygous B6.OT-II mice to generate
B6.OTIIgfp+/2 mice.
The first aim of this study was to determine the effect of CT on
antigen-specific T cell migration. Initially, GFP OT-II lympho-
cytes were adoptively transferred into C57BL/6 recipients to
examine the effect of CT on the migration of antigen-specific T
Table 1. Distribution of Evans Blue dye after i.n. administration.
12 ml Evans Blue 20 ml Evans Blue
Time after inoculation Time after inoculation
LOCATION 0 h 1 h 4 h 22 h 0 h 1 h 4 h 22 h
nasal cavity +++a +++ +++ +++ +++ +++ +++ +++
lung 2 2 2 + 2 2 2 2 2 2 +++ +++ +++ +++
lung and stomach 2 2 2 ++ +++ 2 2 2 2 2 2 +++ +++ 2 2 2
a+ indicates the presence of dye, in relative amounts, - indicates its absence from the organ.
doi:10.1371/journal.pone.0059934.t001
Figure 3. Intranasal administration of CT with OVA increases the number of GFP OT-II cells in draining lymph node. GFP+/2 OT-II cells
were injected into C57BL/6 mice. One day later, mice were i.n. immunized with PBS, 5 mg CT, 5 mg CT with 25 mg OVA or 25 mg OVA alone. Five days
after immunization, the number of GFP+/2 OT-II (GFP, Va2, CD4+) cells in the PLN, MLN, cervical lymph nodes (CLN) and mediastinal lymph nodes
(MeLN) were enumerated by flow cytometry. Shown are the number of cells detected in the PLN, MLN and CLN of individual mice (symbols). The
MeLN of groups of 3 mice were pooled (each symbol representing a pool of 3 mice). The columns indicate the average of each treatment group. Data
were obtained from 2 individual experiments. *denotes P,0.05 (one way ANOVA).
doi:10.1371/journal.pone.0059934.g003
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cells. Administration of CT alone to GFP OT-II recipient animals
did not alter the migration pattern of antigen specific CD4+ T
cells, which were only detectable in secondary lymphoid tissues.
This data suggests that the mucosal adjuvant CT, in the absence of
antigen, does not alter the migration pattern of naı¨ve antigen
specific CD4+ T cells compared to PBS controls.
Naı¨ve lymphocytes are programmed to continuously recirculate
from blood through secondary lymphoid tissue to blood [42] for
the duration of their lifespan, assuming they do not come in
contact with APCs presenting antigen [43]. Therefore naı¨ve
lymphocytes migrate only to secondary lymphoid organs but
memory T cells migrate to non-lymphoid organs [44]. Our
findings correlate with previous work by Sydora et al. who
reported the inability of naı¨ve lymphocytes obtained from
secondary lymphoid tissues to enter the IEL compartment of the
gut after adoptive transfer [45].
Further studies focused on the effect of co-administration of CT
with antigen, via the oral or i.n route, on the migration and
division pattern of adoptively transferred GFP+/2 OT-II cells.
Based on previous findings by Kato et al., it was important to
minimize the amount of OVA administered to mice, since high
oral doses of OVA are known to induce unresponsive OVA-
specific T cells in mucosal inductive sites [46]. Furthermore, it has
been established that i.n. immunization is more efficient, as it
requires lower doses of antigen to induce T cell proliferation
compared with oral immunization [3,37,46]. This study then
examined the effect of mucosally administered CT and antigen on
CD4+ T cell numbers. The results from this study identified that in
comparison with OVA alone, co-administration of CT and OVA
via the oral route significantly increased the number of GFP+/2
OT-II cells in the MLN and PP 5 days after immunization.
Similarly, 5 days after i.n. immunization, the number of GFP+/2
OT-II cells was increased in the MeLN of mice immunized with
CT and OVA. In addition to draining LN, the NALT is also
recognized as an important site for induction of mucosal immune
responses following intranasal administration of antigen. However,
our analysis of NALT following i.n. immunization revealed
negligible numbers of OT-II T cells present within this compart-
ment, irrespective of the immunization treatment, and therefore
no conclusions can be drawn on the effect of CT administration on
antigen specific T cell activation in the NALT using this
technique.
Figure 4. Intranasal administration of OVA with the adjuvant CT results in an increased proliferation of CFSE labeled OT-II cells
in vivo. CFSE -labeled OT-II cells (56106) were adoptively transferred into C57BL/6 mice. One day after transfer, mice were i.n immunized with either
PBS, CT, OVA or CT with OVA (n= 3 per group). Five days after immunization, MeLN (pooled), CLN and MLN were removed and analyzed using flow
cytometry to determine the presence and number of divisions undergone by CFSE OT-II cells in vivo. Propidium iodide (PI) was used to exclude dead
cells from the analysis. (A) Shown is a representative histogram from one individual animal of each group. The number of dividing CFSE-labeled, PI
negative, Va2+, CD4+ T cells in the MeLN (B) and CLN (C) was determined per 5610e5 lymphocytes. Data are representative of 3 individual
experiments. *denotes P,0.05, Students’ t-test.
doi:10.1371/journal.pone.0059934.g004
Cholera Toxin and T Cell Numbers in Lymph Nodes
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e59934
Our observations suggest that CT functions as a mucosal
adjuvant by increasing the number of antigen-specific CD4+ T
cells in immunized mice. This increase in antigen-specific T cell
numbers after immunization of antigen with CT has been
reported by others [14,22]. Hornquist et al. reported a 20 to 40
fold increase in the frequency of primed antigen-specific T cells
after oral immunization with CT and keyhole limpet hemocyanin
(KLH) compared with mice immunized with KLH alone [14].
Taken together, findings from this study and others highlight that
co-administration of antigen with CT increases the number of
antigen-specific T cells in vivo.
It was hypothesized that the CT-induced increase in antigen-
specific CD4+ T cell numbers could be due to 1) equivalent
numbers of cells undergoing more rounds of cellular divisions in
response to the antigen, 2) the induction of more T cells to divide,
or 3) increased migration of antigen-specific T cells to a site of
antigen exposure. To address these hypotheses, adoptive transfer
of CFSE-labeled OT-II cells was employed, enabling the
visualization of cellular division in vivo. A significant increase in
CD4+ T cell numbers was evident due to the co-administration of
CT and OVA in the draining lymph node of i.n or orally
immunized animals. In addition, our data showed that CT did not
alter the number of cellular divisions undergone by antigen-
specific CD4+ T cells in vivo at this timepoint, as the CFSE division
profile was similar in both treatment groups. As the findings from
these studies were not definitive, an in vitro study was performed to
elucidate the effect of CT on the kinetics of cellular division
without cellular migration affecting the outcome of the experi-
ment. Indeed, these in vitro experiments confirmed our in vivo
observations and no effect of CT on the number of cellular
divisions or the kinetics of division was noted. Whether CT has
a similar effect when co-administered with a different antigen
remains to be determined. Furthermore, as our studies did not
examine apoptosis rates of antigen-specific CD4+ T cells, the
contribution of CT-induced apoptosis of antigen specific CD4+ T
cell number in vivo remains to be eluded.
It has been previously shown that CT+OVA induces the
expression of a4b7 integrin on OT-I CD8+ T cells, which
ultimately effects the migration pattern of CD8+ T cells in vivo
[36]. In our study, we did not detect any expression of a4b7
integrin on OT-II CD4+ T cells 5 days post oral immunization
with CT+OVA. It should be noted that the studies examining
a4b7 integrin expression on CD8+ T cells used twice as much CT
and OVA compared to the amounts used in our study, and this
may have an effect on the levels of a4b7 expression observed.
Further studies need to be performed to determine the effect of
oral immunization with CT+OVA on a4b7 integrin expression by
CD4+ T cells in vivo.
Overall, this study identified that the adjuvant effect of CT on
antigen-specific CD4+ T cells is not due to altering the pattern of
cellular migration of antigen-specific CD4+ T cells into other non-
mucosal effector sites, nor due to a modification of the kinetics of
cellular division as demonstrated in a controlled in vitro system, but
immunization with CT affects immune responses by increasing the
number of CD4+ antigen specific T cells. So how does CT increase
the number of antigen specific T cells when co-administered with
antigen? CT is known to facilitate luminal antigen transport across
the epithelium by increasing gut permeability, leading to increased
access of antigen to the immune system [10]. DCs in the
underlying mucosa can move in response to enterotoxin adjuvants
that enter via M cells [47]. In addition, DCs can open tight
junctions between epithelial cells, and use dendrites to directly
sample antigen from outside the epithelium [48]. The DC can
undergo phenotypic and functional maturation [49], upregulating
membrane molecules important for T cell stimulation such as
MHC antigens, B7.1, B7.2, adhesion molecules and receptors for
chemokines [50]. This process allows them to exit inflamed tissue
and to migrate to draining lymph nodes to prime naı¨ve T cells.
Anjuere et al. identified that DCs isolated from the MLN of mice
orally immunized with CT were potent activators of naı¨ve T cells,
could be transferred to naı¨ve animals and induced a Th2 immune
response [51]. Similarly, CT can activate DCs when administered
via the i.n. route. Porgador et al. identified NALT DCs are the
predominant APC involved in the induction of immunity after i.n.
co-administration of OVA and CT, and that DCs isolated from
the CLN or NALT of i.n. immunized mice could stimulate OVA-
specific T cells in vitro [52].
Furthermore, conventional DCs are essential for the priming of
antigen-specific CD4+ T cell responses during vaccination with
antigen and CT [20]. This may be due to the direct effect that CT
has on DCs, eg. inducing their maturation, and/or increasing the
expression of HLA molecules, costimulatory molecules and
functional CCR7 and CXCR4 chemokine receptors, which may
render DCs responsive to migratory stimuli towards secondary
lymphoid organs [23–25]. CT also promotes DCs to drive Th2
responses by inhibiting the production of IFN-g, IL-12 and TNFa
[23,53–55], by enhancing ICAM-1 expression and the production
of cytokines such as IL-10 and IL-6, which are important for Th2
cell differentiation [56], as well as through the induction of
a population of IL-10 producing regulatory T cells [56].
The findings reported here suggest that CT increases the
number of OVA-specific CD4+ T cells in vivo via an indirect effect,
possibly via antigen presenting cells, such as the dendritic cell.
Dendritic cells reside in the NALT, Peyer’s patches and MLN
where they can easily access foreign antigen and can be affected by
adjuvants such as CT [51,52]. In this study, the direct effect of CT
on activation and migration of dendritic cells in vivo was not
analyzed, and future work examining this area may identify the
mechanism whereby CT functions as a mucosal adjuvant. In
addition, to further understand effects of CT on CD4+ T cells
responses and improve vaccine design, studies investigating in
detail the longevity memory T cell responses are also warranted.
Figure 5. Increased proliferation of OT-II cells stimulated with
CT and OVA pulsed BMDCs. BMDC were pulsed with CT or media
(dashed line), OVA peptide (black line) or OVA peptide with CT (grey
line) and cultured with CFSE-labeled OT-II lymphocytes for 4 days.
Lymphocyte proliferation was determined using flow cytometry. PI was
used to exclude dead cells from the analysis. The flow cytometry plots
represent cells harvested from triplicate cultures. Data are representa-
tive of 2 independent experiments.
doi:10.1371/journal.pone.0059934.g005
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